HELP Apheresis in the Treatment of Sepsis
- 1 January 1998
- journal article
- research article
- Published by Wiley in Artificial Organs
- Vol. 22 (1) , 43-46
- https://doi.org/10.1046/j.1525-1594.1998.06011.x
Abstract
Heparin induced extracorporeal lipoprotein fibrinogen precipitation (HELP) is an established procedure for removal of low-density lipoprotein (LDL) cholesterol, lipoprotein (a), and fibrinogen in patients with severe hypercholesterolemia. In vitro studies revealed that HELP also removes endotoxin, tumor necrosis factor α (TNF-α) and C-reactive protein (CRP). With the intention to treat, we applied this procedure to 4 patients with severe gram-negative sepsis with highly elevated endotoxin blood levels. Nine treatments were performed, 6 using the standard HELP precipitating buffer and 3 without addition of heparin to the precipitating buffer. Heparin was omitted from the precipitating buffer to avoid fibrinogen depletion in patients at risk (low fibrinogen, postoperative). The average processed plasma volume was 3,386 ml in the standard and 2,963 ml in the modified treatment. Mean reductions (%) in plasma solute concentrations were (standard/modified procedure) as follows: endotoxin, 50/57; TNF-α, 25/5; CRP, 49/55; fibrinogen, 49/6; total cholesterol, 38/5; and apolipoprotein B (Apo B), 41/2. Both treatment modalities were equally effective in removing endotoxin and CRP. With the modified precipitation buffer, fibrinogen was not removed. To further simplify the extracorporeal treatment, we have designed a closed-loop circuit with 2 adsorbers in series, one for removal of TNF-α (dextran sulfate modified cellulose) and the other for removal of endotoxin (DEAE-cellulose). In vitro evaluation confirmed very efficient endotoxin and TNF-α removal from plasma. This system is very simple, operates at physiological pH, and uses adsorbers already in clinical use for other purposes.Keywords
This publication has 21 references indexed in Scilit:
- Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion ProteinNew England Journal of Medicine, 1996
- Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substancesKidney International, 1995
- A second large controlled clinical study of E5, a monoclonal antibody to endotoxinCritical Care Medicine, 1995
- Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study GroupPublished by American Medical Association (AMA) ,1995
- Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study GroupPublished by American Medical Association (AMA) ,1994
- Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-inimobilized fiberThe American Journal of Surgery, 1994
- A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative SepsisJAMA, 1991
- A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study GroupPublished by American Medical Association (AMA) ,1991
- Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coliNew England Journal of Medicine, 1982